<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Assessment and management of anorexia and cachexia in palliative care</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Assessment and management of anorexia and cachexia in palliative care</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Assessment and management of anorexia and cachexia in palliative care</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eduardo Bruera, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rony Dev, DO</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas J Smith, MD, FACP, FASCO, FAAHPM</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H22882384"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic review will review the clinical assessment and management of anorexia and cachexia in palliative care patients. Other topics related to cancer anorexia and cachexia are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2816.html" rel="external">"Management of cancer anorexia/cachexia"</a>.)</p><p></p><p class="headingAnchor" id="H22882391"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Anorexia is defined as either loss of appetite or reduced caloric intake [<a href="#rid1">1</a>].</p><p>Cachexia is a hypercatabolic state that is defined by an accelerated loss of skeletal muscle in the context of a chronic inflammatory response. It has been best described in the setting of cancer but is also seen in older adults and patients with other advanced chronic illnesses including acquired immunodeficiency syndrome (AIDS), heart failure, chronic kidney failure, and chronic obstructive pulmonary disease (COPD) [<a href="#rid2">2</a>]. Although loss of appetite is common among patients with advanced serious illness, the profound weight loss seen with cachexia cannot be entirely attributed to poor caloric intake and is often due to systemic inflammation, metabolic alterations, and neurohormonal changes. In contrast to simple starvation, cachexia is not reversed by the supplementation of calories [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia", section on 'Definition and classification of severity'</a>.)</p><p>The combined symptom burden of anorexia, the loss of appetite, and cachexia, unintentional weight loss, is often referred to as the anorexia-cachexia syndrome.</p><p>Cachexia is distinct from sarcopenia, which is defined by loss of skeletal muscle mass to an amount that is two standard deviations below sex-specific normal values for young adults [<a href="#rid4">4</a>]. Unlike cachexia, sarcopenia does not require the presence of weight loss. Muscle loss without the loss or gain of fat mass is known as sarcopenic obesity, which is prevalent in older adults [<a href="#rid5">5,6</a>] and is also noted in patients with advanced cancer [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H527426901"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H527426937"><span class="h2">Anorexia</span><span class="headingEndMark"> — </span>Anorexia is a common symptom in palliative care patients, especially among older adults [<a href="#rid8">8</a>]. In one observational series of 3030 palliative care patients with a variety of illnesses, the frequency of moderate or severe anorexia was 26 percent [<a href="#rid9">9</a>]. Anorexia usually results in reduced caloric intake, malnourishment, and weight loss. Poor nutritional intake is common across a variety of chronic disease states such as:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer</strong> – Anorexia is common in patients with advanced cancer. Nutritional intake is often inadequate to support basal metabolic demand in up to 40 percent of this population [<a href="#rid10">10,11</a>]. (See  <a class="medical medical_review" href="/d/html/2816.html" rel="external">"Management of cancer anorexia/cachexia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic kidney disease</strong> – Anorexia is common in patients with chronic kidney disease (CKD). Anorexia affects 30 to 40 percent of adult patients on maintenance hemodialysis and is associated with increased rates of hospitalization, poor quality of life, and increased mortality [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Malnutrition'</a> and  <a class="medical medical_review" href="/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> – The majority of patients with heart failure do not obtain adequate caloric intake or nutrients [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COPD</strong> – Among patients with chronic obstructive pulmonary disease (COPD), the prevalence of malnutrition is roughly 20 to 40 percent in outpatients and up to 70 percent for inpatients with respiratory failure. (See  <a class="medical medical_review" href="/d/html/1440.html" rel="external">"Malnutrition in advanced lung disease", section on 'Frequency of malnutrition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other conditions</strong> – The frequency of anorexia in other conditions such as end-stage liver disease and human immunodeficiency virus (HIV)/AIDS is discussed separately. (See  <a class="medical medical_review" href="/d/html/86295.html" rel="external">"Issues in HIV/AIDS in adults in palliative care", section on 'Anorexia and tissue wasting'</a> and  <a class="medical medical_review" href="/d/html/86296.html" rel="external">"Palliative care for patients with end-stage liver disease", section on 'Other symptoms'</a>.)</p><p></p><p class="headingAnchor" id="H527426943"><span class="h2">Cachexia</span><span class="headingEndMark"> — </span>The prevalence of cachexia in palliative care populations varies widely (from 12 to 85 percent on one report [<a href="#rid14">14</a>]), in part because of variable diagnostic criteria. (See <a class="local">'Definitions'</a> above.)</p><p>The prevalence of cachexia also varies according to disease. Prevalence ranges from 5 to 20 percent in chronic heart failure to 60 percent in COPD and as high as 85 percent in advanced cancer, particularly certain types such as pancreatic, gastric, and lung cancer [<a href="#rid15">15-17</a>]. (See  <a class="medical medical_review" href="/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia"</a>.)</p><p>Cachexia is also highly prevalent in moderate to advanced stages CKD. Loss of weight affects between 18 to 75 percent of patients with CKD, and the prevalence depends in part on patient characteristics (eg, requirement for maintenance hemodialysis [<a href="#rid18">18</a>]) and the presence of comorbid conditions such as heart failure, diabetes mellitus, or liver disease [<a href="#rid19">19</a>].</p><p>The incidence of cachexia in patients living with HIV has decreased with the introduction of effective antiretroviral therapy (ART). In the United States, during the era of effective ART, the prevalence of cachexia among patients living with HIV declined from approximately 30 percent to 18 percent between 2000 and 2022 [<a href="#rid20">20-22</a>]. Nevertheless, cachexia is more prevalent among individuals with later stages of disease (eg, AIDS) and those living in areas with limited access to antiretroviral medications. (See  <a class="medical medical_review" href="/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents"</a>.)</p><p class="headingAnchor" id="H22882398"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H549219003"><span class="h2">Anorexia</span><span class="headingEndMark"> — </span>The pathogenesis of anorexia is complex and related to multiple issues such as molecular alterations, lack of appetite, medications, and aging.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signaling molecules</strong> – Adequate caloric intake is dependent on multiple factors, including the palatability of food, which is controlled by the cranial nerves (the olfactory, glossopharyngeal, and facial), and the feeling of satiety, which is mediated by the autonomic sensory nerves innervating the proximal gastrointestinal tract and contained in the afferent arm of the vagus nerve.</p><p></p><p class="bulletIndent1">Nutritional intake is coordinated by the brain, primarily in the hypothalamic nuclei, which integrates signals from cognitive, visual, and sensory stimuli as well as activity of the gastrointestinal tract. A host of signaling molecules in the brain exert stimulating or inhibiting control of appetite [<a href="#rid23">23-27</a>], including neurotransmitters (serotonin, dopamine, histamine), hormones such as ghrelin [<a href="#rid28">28,29</a>] and leptin [<a href="#rid30">30,31</a>], corticotropin-releasing factor, neuropeptide Y, alpha-melanocyte-stimulating hormone, and others  (<a class="graphic graphic_table graphicRef90107" href="/d/graphic/90107.html" rel="external">table 1</a>). Aberrancies in these signaling pathways may contribute to anorexia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lack of appetite</strong> – Lack of appetite is frequently seen in patients with many kinds of advanced illness (eg, heart failure, cancer, chronic kidney disease [CKD], chronic obstructive pulmonary disease [COPD]). It is also seen in patients with local factors such as thrush or mouth sores and can be due to many chemotherapy agents. In fact, a chronic illness affecting any organ system can cause anorexia and weight loss. The symptom of anorexia in the setting of infection, trauma, or cancer may represent an important adaptive response that allows an organism to mobilize energy reserves in order to sustain the increased metabolism required to wage an immune response and heal injuries or repair the destruction from rapidly dividing malignant cells [<a href="#rid32">32,33</a>].</p><p></p><p class="bulletIndent1">Lack of appetite can also be a consequence of chronic fatigue or nausea, which may be barely noticeable; altered taste, depression, pain, xerostomia, disorders of gastrointestinal motility (including gastroparesis), constipation, and food aversions can also contribute. These symptoms are referred to as "secondary nutrition impact symptoms." (See <a class="local">'Secondary nutrition impact symptoms'</a> below.)</p><p></p><p class="bulletIndent1">Decreased appetite is a major component of the "failure to thrive" (FTT) syndrome, which is described by The National Institute of Aging as a "syndrome of weight loss, decreased appetite and poor nutrition, and inactivity, often accompanied by dehydration, depressive symptoms, impaired immune function, and low cholesterol" [<a href="#rid34">34</a>]. In geriatric practice, FTT describes a point further along a geriatric functional continuum that is closer to full dependence and death, with "frailty as a mid-point between independence and pre-death" [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/3018.html" rel="external">"Failure to thrive in older adults: Evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Anorexia is associated with medications such as amphetamines, antibiotics, cancer-directed therapies (especially many chemotherapy and targeted agents), opioids [<a href="#rid36">36</a>], antihistamines, <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>, <a class="drug drug_general" data-topicid="10262" href="/d/drug information/10262.html" rel="external">ranolazine</a>, and certain antidepressants. Chemotherapy can also induce muscle wasting [<a href="#rid37">37</a>]. Chronic opioid use can result in hypogonadism and subsequent loss of lean body mass. In the setting of end-stage kidney disease (ESKD), male patients tend to have increased symptoms of anorexia, suggesting a possible role for sex hormones [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aging</strong> – Aging may also contribute to anorexia. Food intake gradually diminishes with age, much of which is an appropriate response to decreased energy needs due to reduced physical activity and decreased resting energy expenditure. Changes in taste and smell can also lead to a decreased desire to eat [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/3016.html" rel="external">"Geriatric nutrition: Nutritional issues in older adults", section on 'Inadequate dietary intake'</a> and  <a class="medical medical_review" href="/d/html/2770.html" rel="external">"Approach to the patient with unintentional weight loss", section on 'Etiologies'</a>.)</p><p></p><p class="headingAnchor" id="H22882412"><span class="h2">Cachexia</span><span class="headingEndMark"> — </span>The pathogenesis of cachexia has been best studied in patients with cancer. Cytokines, or polypeptides released mainly by immune cells, are often associated with the hypermetabolic states seen with cancer cachexia. This inflammatory response may play a unifying role in the cachexia that occurs with injury, infection, and chronic illness other than cancer. Further details on these and other molecular mechanisms of cancer cachexia are discussed separately. (See  <a class="medical medical_review" href="/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia", section on 'Pathogenesis'</a>.)</p><p>In patients with non-cancer-related cachexia, the etiology is also multifactorial and not related to inflammation alone. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypogonadism</strong> – Hypogonadism is a common endocrine cause of wasting in patients with advanced immunosuppression (eg, HIV). It is also associated with chronic opioid use [<a href="#rid40">40</a>]. Hypogonadism is associated with a higher symptom burden, markers of inflammation, and worse survival [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/13969.html" rel="external">"Hypogonadism in males with HIV"</a> and  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Neuroendocrine effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac disease</strong> – Cardiac cachexia is mediated by changes in catecholamines, cortisol, natriuretic peptides, and proinflammatory cytokines, including tumor necrosis factor (TNF) alpha, interleukin 1 (IL-1), and IL-6 [<a href="#rid42">42,43</a>]. Endocrine dysfunction, including activation of the renin-angiotensin-aldosterone-system, increased levels of ghrelin [<a href="#rid44">44</a>], and insulin resistance [<a href="#rid45">45</a>], also may play a role, as do other hormones such as adiponectin [<a href="#rid46">46</a>]. Heart failure resulting in decreased bowel perfusion or edema may also contribute to nutritional deficiencies and fat malabsorption. (See  <a class="medical medical_review" href="/d/html/110747.html" rel="external">"Palliative care for patients with advanced heart failure: Decision support and management of symptoms", section on 'Nausea and cachexia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary disease</strong> – Malnutrition associated with advanced lung disease has been termed the “pulmonary cachexia syndrome.” It is a well-recognized feature of advanced COPD. Potential contributory factors to the progressive reduction in lean body mass include changes in metabolism and caloric intake, aging, lack of exercise, fatigue, tissue hypoxia, inflammation, and medications [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/1440.html" rel="external">"Malnutrition in advanced lung disease", section on 'Contributing factors'</a>.)</p><p></p><p class="bulletIndent1">A role for myostatin, a member of the transforming growth factor-beta superfamily that functions as a negative regulator of muscle growth, has been suggested by the finding of significantly elevated serum myostatin levels in patients with stable COPD compared with healthy controls [<a href="#rid48">48</a>]. Myostatin levels correlated inversely with total body skeletal muscle mass and body mass index (BMI).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic kidney disease</strong> – In CKD, anorexia and malnutrition may contribute to weight loss, but they are not responsible for the pathogenesis of cachexia. Factors such as systemic inflammation, alterations of hormones (including vitamin D deficiency), increased energy expenditure, insulin resistance, metabolic acidosis, and other mechanisms contribute to cachexia in CKD [<a href="#rid49">49,50</a>].</p><p></p><p class="headingAnchor" id="H22882419"><span class="h1">CLINICAL ASSESSMENT</span></p><p class="headingAnchor" id="H4227696291"><span class="h2">History</span><span class="headingEndMark"> — </span>The clinical assessment for patients with anorexia or cachexia includes a careful history that is focused on nutritional issues, including risk factors that compromise the ability to obtain or take in nutrition. All patients with advanced incurable illness should be screened for loss of appetite or decreased caloric intake and unintentional weight loss. Screening can be performed either by clinicians or a licensed nutritionist. (See  <a class="medical medical_review" href="/d/html/2196.html" rel="external">"Approach to symptom assessment in palliative care", section on 'Lack of appetite'</a>.)</p><p class="headingAnchor" id="H345696618"><span class="h3">Contributing conditions</span><span class="headingEndMark"> — </span>Patients should be evaluated for medical conditions and medications that can contribute to anorexia or cachexia. Notably, these also include metabolic abnormalities that are potentially reversible, which may go undetected and contribute to loss of appetite or decreased lean body mass.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypogonadism</strong> – Hypogonadism is especially common in males with cancer [<a href="#rid51">51,52</a>]. In male patients without cancer, the clinical features of hypogonadism, including those that should prompt diagnostic evaluation, are discussed separately. (See  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism", section on 'Candidates for testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenal insufficiency</strong> – We screen for adrenal insufficiency in cancer patients who have bilateral adrenal metastasis or in those without cancer and a clinical suspicion for adrenal insufficiency. (See  <a class="medical medical_review" href="/d/html/159.html" rel="external">"Clinical manifestations of adrenal insufficiency in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid abnormalities</strong> – We screen all patients with unintentional weight loss for thyroid abnormalities (eg, hypothyroidism, hyperthyroidism). (See  <a class="medical medical_review" href="/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastroparesis</strong> – Gastroparesis is common in patients who have diabetes mellitus; experience stress; have a history of surgery to the stomach, small bowels, or colon; and are critically ill. In addition, patients with cancer who have received chemotherapy or radiation therapy are at risk for developing gastroparesis.</p><p></p><p class="bulletIndent1">In patients with cancer, the etiology of gastroparesis and early satiety is often multifactorial and can include chemotherapy-induced autonomic dysfunction and medications such as opioids or anticholinergics, radiation enteritis, and tumor infiltration, or it can be the result of a paraneoplastic syndrome. It is easily diagnosed by history of early satiety and can sometimes be successfully treated. (See  <a class="medical medical_review" href="/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2532.html" rel="external">"Treatment of gastroparesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Among patients with cancer, some cancer-directed treatments are associated with sarcopenia (androgen deprivation therapy, <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>), which may also contribute to decreased lean body mass. (See  <a class="medical medical_review" href="/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia", section on 'Contribution of cancer treatment'</a>.)</p><p></p><p class="bulletIndent1">For patients without cancer, other medications may impair appetite. (See <a class="local">'Anorexia'</a> above.)</p><p></p><p class="headingAnchor" id="H1305734211"><span class="h3">Secondary nutrition impact symptoms</span><span class="headingEndMark"> — </span>Patients with anorexia and cachexia should also be assessed for secondary nutrition impact symptoms (S-NIS) or symptoms that may impact appetite and caloric intake. These may include symptoms related to the underlying illness, symptoms and syndromes that may contribute to reduced caloric intake, and symptoms that might be the consequence of cachexia  (<a class="graphic graphic_table graphicRef90107" href="/d/graphic/90107.html" rel="external">table 1</a>). In particular, pain, xerostomia, nausea, constipation, and depression are frequent in patients with a chronic illness and may result in decreased caloric intake if not adequately treated [<a href="#rid51">51,53</a>]. In one study of 151 patients referred to a cancer cachexia clinic, the median number of S-NIS was three, and the most common were early satiety, constipation, nausea/vomiting, and depressed mood [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H2076320016"><span class="h3">Psychosocial distress</span><span class="headingEndMark"> — </span>Anorexia and/or cachexia often results in psychosocial distress for both patients and their caregivers [<a href="#rid54">54-56</a>]. (See  <a class="medical medical_review" href="/d/html/96044.html" rel="external">"Overview of psychosocial issues in the adult cancer survivor", section on 'Caregivers'</a>.)</p><p>Clinicians should assess patients for psychological distress such as depression and anxiety. A prospective study of patients with advanced cancer found that patients who experienced weight loss of at least 10 percent during the previous six months reported higher deterioration of body image than did patients without such weight loss, and body-image dissatisfaction had a strong association with psychosocial outcomes (anxiety, depression, decreased sexual interest and enjoyment) [<a href="#rid54">54</a>]. </p><p>In a qualitative study, family caregivers universally noted changes in oral intake at the end of life [<a href="#rid57">57,58</a>]. Bereaved caregivers who were interviewed reported a sense of helplessness and guilt associated with a loved one losing weight and felt that not enough education and psychological support was provided by health care providers regarding hydration and nutrition at the end of life. Some caregivers accepted decreased intake as part of the dying process, while others preferred to support oral intake [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H794183896"><span class="h2">Assessing nutritional status</span></p><p class="headingAnchor" id="H4195081434"><span class="h3">Subjective measures of nutritional status</span><span class="headingEndMark"> — </span>Subjective measures of nutritional status can be measured using brief nutritional questionnaires that can be completed by the patient. These include dietary recalls, Edmonton Symptom Assessment System (ESAS, appetite score ≥3) or Visual Analog Scale (VAS, ≤70) for anorexia, and the Anorexia/Cachexia Subscale of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT-A/CS) [<a href="#rid59">59</a>]. Recommended diagnostic criteria for anorexia include a cutoff value of ≤70 on the VAS for appetite and a cutoff value of ≤37 on the FAACT-A/CS [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H1559369640"><span class="h3">Malnutrition assessment tools</span><span class="headingEndMark"> — </span>We endorse routine use of a brief assessment tool for malnutrition screening [<a href="#rid61">61</a>]. Several screening tests have been developed to assess for malnutrition, including the Patient-Generated Subjective Global Assessment (PG-SGA), the mini nutritional assessment (MNA), the Malnutrition Universal Screening Tool (MUST), and the Simplified Nutritional Appetite Questionnaire (SNAQ). No single screening tool has been universally agreed upon as the best way to detect malnutrition in patients with cancer or other chronic illnesses. At our institution, the PG-SGA is used as a malnutrition assessment tool.</p><p class="bulletIndent1"><span class="glyph">●</span>The PG-SGA is well established and validated with other objective nutritional measurements [<a href="#rid62">62</a>]. It incorporates information from patients (weight history, food intake, functional status, symptoms affecting food intake), assessments made by health care professionals (comorbid conditions, corticosteroid use, fever), and assessments made by physical examination [<a href="#rid63">63</a>]. PG-SGA is validated in cancer patients of all ages and in hospitalized patients, but it does take time and a well-trained person to complete. In one review, the average time required to complete the PG-SGA by a patient and responsible evaluator was 5 to 15 minutes [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Nutritional Risk Screening (NRS) 2002 has two components: a screening assessment for undernutrition (estimated with three variables: body mass index (BMI), percent recent weight loss, and change in food intake) and an estimate for disease severity (which ranges from a score of zero for those with chronic illnesses or a hip fracture to three for those in the intensive care unit with an Acute Physiology and Chronic Health Evaluation [APACHE] score of 10) [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/d/html/3016.html" rel="external">"Geriatric nutrition: Nutritional issues in older adults", section on 'Screening tools'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The MUST has been validated in cancer patients and hospitalized patients who are acutely ill and predicts length of stay and mortality. It is a simple tool that incorporates BMI, weight loss, and an acute disease effect score [<a href="#rid65">65-67</a>].</p><p></p><p>The specific cachexia domains covered by some of these screening tools include stores depletion, muscle mass and strength, anorexia or reduced food intake, catabolic drivers, and functional/psychosocial defects  (<a class="graphic graphic_table graphicRef90106" href="/d/graphic/90106.html" rel="external">table 2</a>) [<a href="#rid68">68</a>].</p><p>These and other malnutrition screening tools are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/3016.html" rel="external">"Geriatric nutrition: Nutritional issues in older adults", section on 'Screening tools'</a>.)</p><p class="headingAnchor" id="H3414725619"><span class="h3">Nutritional intake diary</span><span class="headingEndMark"> — </span>Nutritional intake dietary records kept by the patient at home (either with retrospective or prospective reporting) can be used to measure caloric intake. Retrospective reporting is limited by recall bias, while prospective recordings of dietary intake require several days of assessments to be reliable [<a href="#rid69">69</a>]. For prospective diet diaries, a three-day collection interval [<a href="#rid70">70</a>] seems to be a feasible and accepted approach to determining caloric intake. An alternative approach used in research, which estimates the percentage of food portions consumed by patients by trained proxies (either a nurse or a volunteer), has shown good correlation with actual caloric intake and is more reliable than a 24-hour recall method [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H2916187686"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination focuses on evaluating for loss of subcutaneous fat, muscle wasting (temporal region, deltoids, and quadriceps with loss of bulk and tone by palpation), edema (sacral or ankle), and ascites. The initial stages of weight loss may be masked in patients with obesity. Other anthropometric indicators of nutritional status, such as mid-upper arm circumference and skinfold measurement, can be used to objectively document muscle wasting and loss of subcutaneous fat. However, these are more often used in the research setting and are rarely needed in the clinic.</p><p class="headingAnchor" id="H772669371"><span class="h2">Objective measures</span><span class="headingEndMark"> — </span>The most used objective measures of nutritional status are serial measurement of body weight, anthropometrics, biochemical, and laboratory measures, and functional measures including the six-minute walk and hand grip strength tests.</p><p class="headingAnchor" id="H2274276531"><span class="h3">Laboratory tests</span><span class="headingEndMark"> — </span>Laboratory measures (eg, albumin, transferrin) can be used to assess nutritional status, and some screening tools (eg, the Nutrition Risk Index) include a measurement of serum albumin (see <a class="local">'Malnutrition assessment tools'</a> above). In addition to screening for malnutrition, the presence of a low albumin can indicate increased risk of mortality.</p><p class="headingAnchor" id="H345697301"><span class="h3">Assessment of body weight and other anthropometric measures</span><span class="headingEndMark"> — </span>Serial measurements of body weight offer the simplest screen for nutritional adequacy and change in nutritional status. The weight and height of a patient are easily obtainable and are used to formulate BMI, calculated by an individual’s body mass divided by the square of their height (kg/m<sup>2</sup>). Various values of low BMI (BMI &lt;17, &lt;18.5, or &lt;20) have been used as markers for nutritional deficiency and cachexia. However, BMI accuracy is limited [<a href="#rid72">72</a>], does not take into account age or sex, and fails to distinguish between proportions of bone, lean body mass, or fat. Many chronically ill patients, including those with advanced cancer, have normal to high BMI values reflective of preexisting obesity, with decreased fat-free mass but increased fat mass [<a href="#rid53">53,73</a>].</p><p>These issues were taken into account in the development, by an international consensus group, of a set of proposed diagnostic criteria for the classification of the severity of cancer-associated weight loss, which was developed from a contemporary population-based data set and showed the independent prognostic significance of both percent weight loss and BMI [<a href="#rid74">74</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Weight-stable patients (ie, weight loss±2.4 percent) with BMI ≥25.0 kg/m<sup>2</sup> had the longest survival (29 months): proposed grade 0</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BMI 20 to 25 kg/m<sup>2</sup> and weight loss ≤2.4 percent or BMI ≥28 kg/m<sup>2</sup> and weight loss 2.5 to 6 percent (median survival 14.6 months): proposed grade 1</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BMI 20 to 28 kg/m<sup>2</sup> and weight loss 2.5 to 6 percent or BMI ≥28 kg/m<sup>2</sup> and weight loss 6 to 11 percent (median survival 10.8 months): proposed grade 2</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BMI ≤20 and weight stable or loss of &lt;6 percent, BMI 20 to 28 kg/m<sup>2</sup> and weight loss 6 to 11 percent, BMI 22 to &gt;28 kg/m<sup>2</sup> and weight loss 11 to 15 percent, or BMI ≥28.0 kg/m<sup>2</sup> and weight loss &gt;15 percent (median survival 7.6 months): proposed grade 3</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BMI ≤20 kg/m<sup>2</sup> and weight loss 6 to 11 percent, BMI ≤22 kg/m<sup>2</sup> and weight loss 11 to 15 percent, or BMI ≤28 kg/m<sup>2</sup> and weight loss &gt;15 percent (median survival 4.3 months): proposed grade 4</p><p></p><p>Survival discrimination by grade was observed within specific cancers, stages, ages, and performance states and within an independent validation sample. These data underscore the important prognostic impact of weight loss as well as BMI in cancer patients. Limitations of the study include the variable timeframes used when assessing weight loss and BMI, which pooled data from multiple clinical trials conducted in Canada and France. (See  <a class="medical medical_review" href="/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia", section on 'Classifying severity'</a>.)</p><p class="headingAnchor" id="H345697275"><span class="h2">Evaluating body composition</span><span class="headingEndMark"> — </span>For patients who elect to have interventions for weight loss, it is important to have accurate assessment of lean body mass and body composition. At many centers, body composition can be initially assessed and monitored while on therapy using dual-energy x-ray absorptiometry (DXA), computed tomography (CT), or magnetic resonance imaging (MRI). In the absence of a clinical trial requirement, a weight and appetite diary is usually sufficient, more simple and convenient to obtain, and less expensive.</p><p>Bioelectrical impedance analysis (BIA) is a convenient, portable, and low-cost measure of weight and can estimate fat-free mass and fat mass. However, in cancer patients, BIA may underestimate fat-free mass when compared with DXA and the equipment is not readily available in most institutions [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H22882454"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H3203734134"><span class="h2">General dietary principles</span></p><p class="headingAnchor" id="H20096256"><span class="h3">Dietary and lifestyle modifications</span><span class="headingEndMark"> — </span>Loss of appetite and alterations in appearance because of cachexia are distressing to both patients and their loved ones. The social benefits of being at the dining table with other family members should be encouraged if the patient finds this to be important. The pleasure of tasting food, if it exists, should be emphasized over total caloric intake. In general, patients with anorexia-cachexia syndrome who can eat should have small, frequent meals that are dense in calories (eg, eggs, liquid nutritional supplements). Other strategies to enhance caloric intake include using straws to facilitate intake of fluids or nutritional supplements, eating meals that require little preparation (eg, microwaveable), and resting before meals.</p><p>While some patients may benefit from nutritional supplementation, patients and families should be counseled that increasing caloric intake does not reverse the underlying process and that loss of appetite or unintentional weight loss are common symptoms. In addition, these symptoms are different from starvation and a natural process that occurs at the end of life. (See <a class="local">'Indications for artificial nutritional support'</a> below.)</p><p>Optimizing management of major contributors to anorexia, such as chronic nausea, constipation, taste alterations, dyspnea, and depression, may result in significant improvement. For patients with persistent anorexia, pharmacologic treatments are available that predominantly stimulate appetite; however, they will not reverse cachexia in most patients.</p><p class="headingAnchor" id="H2173216161"><span class="h3">Nutritional consultation</span><span class="headingEndMark"> — </span>Consultation with a nutritionist should be offered to all patients with cachexia in the setting of an advanced life-threatening illness. A dietician may provide important support to patients and their caregivers by helping individual patients meet estimated protein and caloric needs as much as possible and by discouraging potentially harmful dietary supplement use and unproven or extreme diets [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H172482438"><span class="h3">Treatment for gastroparesis</span><span class="headingEndMark"> — </span>Gastroparesis and early satiety may be successfully treated with dietary modification (small, frequent meals, eg, five to six small meals throughout the day) and prokinetic agents, such as <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>. Other options include <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>, and, where available, <a class="drug drug_general" data-topicid="9269" href="/d/drug information/9269.html" rel="external">cisapride</a> and <a class="drug drug_general" data-topicid="8777" href="/d/drug information/8777.html" rel="external">domperidone</a>. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2532.html" rel="external">"Treatment of gastroparesis"</a>.)</p><p class="headingAnchor" id="H2940407047"><span class="h3">Indications for artificial nutritional support</span><span class="headingEndMark"> — </span>Artificial nutrition is not offered to most palliative care patients. While nutrient supplementation might appear ideal to control or reverse malnutrition, there is no evidence that artificial nutrition, including hyperalimentation, prolongs life or improves functional status for the vast majority of chronically ill patients with an advanced life-threatening disease such as cancer or dementia [<a href="#rid77">77</a>].</p><p>For those patients with high-grade bowel obstruction or malabsorption from advanced cancer who might otherwise have a prognosis that is measured in months and good functional status, a short-term trial of home parenteral nutritional support is an option after deliberation among the health care staff, the patient, and family members [<a href="#rid76">76,78,79</a>]. After initiation, the use of <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> needs periodic reevaluation; if the benefits are outweighed by excessive harms, it should be discontinued. In addition, when death appears imminent, any previously initiated nutritional support should be discontinued.</p><p>Initiation and discontinuation of artificial nutrition and hydration near the end of life are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2830.html" rel="external">"The role of parenteral and enteral/oral nutritional support in patients with cancer"</a> and  <a class="medical medical_review" href="/d/html/2568.html" rel="external">"Gastrostomy tubes: Uses, patient selection, and efficacy in adults"</a> and  <a class="medical medical_review" href="/d/html/86250.html" rel="external">"Care of patients with advanced dementia"</a> and  <a class="medical medical_review" href="/d/html/5129.html" rel="external">"Symptom-based management of amyotrophic lateral sclerosis", section on 'Management of swallowing and nutrition'</a> and  <a class="medical medical_review" href="/d/html/14244.html" rel="external">"Stopping nutrition and hydration at the end of life"</a>.)</p><p class="headingAnchor" id="H2693247902"><span class="h2">Patients with cancer</span><span class="headingEndMark"> — </span>The pharmacologic management of cachexia in patients with cancer involves initial therapy with low-dose <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>. <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">Progesterone</a> agents and steroids are alternative options for those who cannot tolerate olanzapine. Further details on the efficacy of these agents are discussed separately. (See  <a class="medical medical_review" href="/d/html/2816.html" rel="external">"Management of cancer anorexia/cachexia", section on 'Pharmacologic treatments'</a>.)</p><p class="headingAnchor" id="H345697946"><span class="h2">Patients without cancer</span></p><p class="headingAnchor" id="H22882601"><span class="h3">HIV/AIDS</span></p><p class="headingAnchor" id="H3400471261"><span class="h4">Antiretroviral therapy</span><span class="headingEndMark"> — </span>When possible, the primary therapy of HIV wasting is treatment of the underlying HIV infection with antiretroviral therapy (ART). In most patients, tissue wasting responds rapidly to ART. (See  <a class="medical medical_review" href="/d/html/86295.html" rel="external">"Issues in HIV/AIDS in adults in palliative care"</a>.)</p><p class="headingAnchor" id="H1943884336"><span class="h4">Megestrol acetate</span><span class="headingEndMark"> — </span>For patients living with HIV or AIDS with anorexia or cachexia despite appropriate ART and addressing other treatable causes of weight loss (eg, malignancy, infection, malabsorption, endocrine disease, kidney disease, psychiatric disorder, hypogonadism), we suggest the addition of <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> to other supportive measures. Megestrol acetate is approved by the US Food and Drug Administration (FDA) for treatment of anorexia, cachexia, or unexplained significant weight loss in patients with AIDS [<a href="#rid80">80</a>].</p><p>Patients should be counseled that the effect of this medication on appetite is limited, that it may not fully restore the lost weight, and that it may not improve survival or quality of life. Patients should also be counseled about risks of this medication, including edema, thromboembolic events, and death.</p><p>We initiate <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> at the lowest effective dose (80 to 160 mg/day) and titrate to a maximum of 800 mg/day to minimize toxicity [<a href="#rid81">81</a>]. Consideration must also be given to cost. Megestrol acetate is expensive (USD $162 to $290 for a 14-day supply of 625 mg/5 mL liquid; $17 to $29 for a 14-day supply of 40 mg tablets [<a href="#rid70">70</a>]).</p><p>Symptomatic improvement in appetite may be seen in less than one week, but weight gain (which only occurs in one-fourth of treated patients) may take several weeks. If it is being prescribed for appetite, we provide a 14-day supply and only refill if it is of benefit and without evidence of toxicity [<a href="#rid82">82</a>].</p><p>There are limited data for the efficacy of <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> to treat anorexia in patients with HIV/AIDS. In a trial of 100 patients with AIDS and cachexia conducted prior to the availability of modern antiretroviral treatment, megestrol acetate resulted in increased daily caloric intake compared with placebo at eight weeks (difference 474 calories, 95% CI -68 to 880 calories) as well as greater weight gain (difference 4.32 kg, 95% CI 2.42 to 6.22 kg) [<a href="#rid83">83</a>]. In a similar trial of 195 patients, a greater percentage of those receiving megestrol acetate gained 5 pounds or more compared with placebo at 12 weeks (64.2 versus 21.4 percent) [<a href="#rid84">84</a>]. However, in a meta-analysis of patients with cachexia related to cancer, HIV/AIDs, and other conditions, megestrol acetate was associated with toxicities including edema and thromboembolic phenomena as well as increased mortality, especially at doses ≥800 mg/day [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H1909183356"><span class="h3">Cardiac cachexia</span><span class="headingEndMark"> — </span>Treatment for anorexia and cachexia in heart failure includes optimizing heart failure management. Nutritional support and physical exercise is often recommended to prevent muscle loss. Cardiac rehabilitation programs in patients with heart failure have been reported to improve functional outcomes and quality of life [<a href="#rid86">86</a>]. This subject is covered in detail separately. (See  <a class="medical medical_review" href="/d/html/110747.html" rel="external">"Palliative care for patients with advanced heart failure: Decision support and management of symptoms", section on 'Nausea and cachexia'</a>.)</p><p class="headingAnchor" id="H1599054420"><span class="h3">Chronic obstructive pulmonary disease</span><span class="headingEndMark"> — </span>Nutritional treatment of pulmonary cachexia syndrome typically includes providing sufficient calories to meet basal energy expenditure and induce weight gain. Treatment options are discussed separately. (See  <a class="medical medical_review" href="/d/html/1440.html" rel="external">"Malnutrition in advanced lung disease", section on 'Nutritional interventions'</a> and  <a class="medical medical_review" href="/d/html/1440.html" rel="external">"Malnutrition in advanced lung disease", section on 'Medications'</a>.)</p><p>Exercise has also been shown to improve the effectiveness of nutritional therapy and to stimulate appetite [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/d/html/1440.html" rel="external">"Malnutrition in advanced lung disease", section on 'General measures for prevention and treatment'</a> and  <a class="medical medical_review" href="/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a>.)</p><p class="headingAnchor" id="H104003655"><span class="h3">Chronic kidney disease</span><span class="headingEndMark"> — </span>Nutritional supplementation may be helpful in patients with protein-energy wasting to reverse the progression to cachexia in adult patients with end-stage kidney disease (ESKD). This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1856.html" rel="external">"Pathogenesis and treatment of malnutrition in patients on maintenance hemodialysis", section on 'Nutritional supplements'</a>.)</p><p>However, the desire to maintain adequate nutrition among patients with ESKD clearly competes with attempts to slow the progression of kidney failure with the use of a low-protein diet. This issue is discussed separately. (See  <a class="medical medical_review" href="/d/html/7178.html" rel="external">"Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Protein intake'</a>.)</p><p class="headingAnchor" id="H3504609754"><span class="h3">End-stage liver disease</span><span class="headingEndMark"> — </span>Protein-calorie malnutrition is common in individuals with end-stage liver disease. Anorexia and cachexia are often anticipated findings in patients who are near death, but these issues need to be handled differently in the palliative care patient hoping to receive a liver transplant. (See  <a class="medical medical_review" href="/d/html/86296.html" rel="external">"Palliative care for patients with end-stage liver disease", section on 'Other symptoms'</a>.)</p><p class="headingAnchor" id="H2813126407"><span class="h2">Treatments needing further study</span></p><p class="headingAnchor" id="H666447112"><span class="h3">Cannabis and cannabinoids</span><span class="headingEndMark"> — </span>For most palliative care patients with anorexia and/or cachexia unrelated to cancer, we do not use synthetic cannabinoids, inhaled marijuana, or ingested cannabidiol oil either as a single agent or in combination with <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> given the limited evidence supporting benefit and the potential risks [<a href="#rid88">88-91</a>]. The limited role of cannabis in treatment of anorexia and cachexia in patients with cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/2816.html" rel="external">"Management of cancer anorexia/cachexia", section on 'Cannabis and cannabinoids'</a>.)</p><p>In the United States, the availability and regulation of <a class="drug drug_general" data-topicid="134930" href="/d/drug information/134930.html" rel="external">medical cannabis</a> and cannabinoids varies by state (see  <a class="medical medical_review" href="/d/html/126970.html" rel="external">"Medical use of cannabis and cannabinoids in adults", section on 'Medical cannabis policy in the United States'</a>). Nevertheless, there are insufficient data for the efficacy of these agents for the treatment of anorexia and cachexia in patients using palliative care [<a href="#rid92">92</a>]. Potential toxicities including hallucinations and psychosis, which is especially concerning for older adults, frail patients, or those who take multiple medications. Further information on cannabis and cannabinoids are presented separately. (See  <a class="medical medical_review" href="/d/html/126970.html" rel="external">"Medical use of cannabis and cannabinoids in adults"</a>.)</p><p class="headingAnchor" id="H3973692566"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>Other therapies have been investigated in the treatment of anorexia and cachexia in patients receiving palliative care. Further studies are necessary prior to incorporating these approaches into routine practice. These are discussed separately. (See  <a class="medical medical_review" href="/d/html/2816.html" rel="external">"Management of cancer anorexia/cachexia", section on 'Insufficient evidence to recommend for or against'</a>.)</p><p class="headingAnchor" id="H2904548686"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Cachexia is also associated with a poor prognosis in patients with advanced disease. In a National Hospice study of terminal cancer, the symptoms of anorexia, weight loss, xerostomia, and dysphagia were all predictive of decreased survival [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia", section on 'Clinical consequences'</a>.)</p><p>In addition to cancer, cachexia in the setting of other illnesses, such as heart failure, chronic kidney disease (CKD), HIV, or chronic obstructive pulmonary disease (COPD), has also been shown to increase the risk of death [<a href="#rid94">94-97</a>]. In addition to its prognostic value, loss of muscle mass is often associated with poor functional status, impaired quality of life, and an increased risk of hospitalization [<a href="#rid98">98,99</a>]. (See  <a class="medical medical_review" href="/d/html/2196.html" rel="external">"Approach to symptom assessment in palliative care", section on 'Performance status, symptoms, and prognosis'</a> and  <a class="medical medical_review" href="/d/html/1440.html" rel="external">"Malnutrition in advanced lung disease", section on 'Effect on mortality and lung function'</a>.)</p><p class="headingAnchor" id="H971632571"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119531.html" rel="external">"Society guideline links: Palliative care"</a>.)</p><p class="headingAnchor" id="H916528899"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topi<sup>c.</sup> We en<sup>co</sup>urage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/141278.html" rel="external">"Patient education: Malnutrition (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/141279.html" rel="external">"Patient education: Malnutrition – Discharge instructions (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22882615"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Anorexia is defined as either loss of appetite or reduced caloric intake. Cachexia is a hypercatabolic state defined by an accelerated loss of skeletal muscle. Both conditions are common in palliative care patients, including those with and without cancer. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Cachexia is associated with a poor prognosis in patients with advanced disease. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical assessment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>History</strong> – The history focuses on nutritional issues, including factors such as pain, xerostomia, nausea, constipation, and depression that may compromise the ability to take in nutrition. (See <a class="local">'History'</a> above.)</p><p></p><p class="bulletIndent2">Patients should be evaluated for other conditions that can contribute to anorexia or cachexia include potentially reversible metabolic or endocrine abnormalities, medication use, and gastroparesis. (See <a class="local">'Contributing conditions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assessing nutritional status</strong> – Various brief assessment tools for nutritional status and malnutrition are available. Nutritional intake dietary records kept by the patient at home can also be used to measure caloric intake. (See <a class="local">'Assessing nutritional status'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Physical examination and objective measures</strong> – We evaluate for loss of subcutaneous fat, muscle wasting (temporal region, deltoids and quadriceps with loss of bulk and tone by palpation), edema (sacral or ankle), and ascites. The initial stages of weight loss may be masked in patients with obesity. (See <a class="local">'Physical examination'</a> above.)</p><p></p><p class="bulletIndent2">Objective measures include serial measurement of body weight, anthropometrics, biochemical, and laboratory measures (eg, albumin, transferrin), and functional measures including the six-minute walk and hand grip strength tests. (See <a class="local">'Objective measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dietary modifications</strong> – Patients should have small, frequent meals that are dense in calories (eg, eggs, liquid nutritional supplements). Other strategies to enhance caloric intake include using straws to facilitate intake of fluids or nutritional supplements. (See <a class="local">'Dietary and lifestyle modifications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nutritional consult</strong> – Consultation with a nutritionist should be offered to all patients with cachexia in the setting of an advanced life-threatening illness. (See <a class="local">'Nutritional consultation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of gastroparesis</strong> – Gastroparesis may also be treated with dietary modification (small, frequent meals, eg, five to six small meals throughout the day) and prokinetic agents. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2532.html" rel="external">"Treatment of gastroparesis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for nutritional support</strong> – Artificial nutrition is not offered to most palliative care patients, as there is no evidence it prolongs life or improves functional status. (See <a class="local">'Indications for artificial nutritional support'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with cancer</strong> – The pharmacologic management of cachexia in patients with cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/2816.html" rel="external">"Management of cancer anorexia/cachexia", section on 'Pharmacologic treatments'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with</strong> <strong>HIV/AIDS</strong> – The primary therapy of HIV wasting is treatment of the underlying HIV infection with antiretroviral therapy (ART). (See  <a class="medical medical_review" href="/d/html/86295.html" rel="external">"Issues in HIV/AIDS in adults in palliative care"</a>.)</p><p></p><p class="bulletIndent2">For patients living with HIV or AIDS with anorexia or cachexia despite appropriate ART and addressing other treatable causes of weight loss (eg, malignancy, infection, malabsorption, endocrine disease, kidney disease, psychiatric disorder, hypogonadism), we suggest the addition of <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> to other supportive measures (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Megestrol acetate'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with other non-cancer conditions</strong> – The management of cachexia for the following non-cancer conditions are discussed separately:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cardiac cachexia (see  <a class="medical medical_review" href="/d/html/110747.html" rel="external">"Palliative care for patients with advanced heart failure: Decision support and management of symptoms", section on 'Nausea and cachexia'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>COPD (see  <a class="medical medical_review" href="/d/html/1440.html" rel="external">"Malnutrition in advanced lung disease", section on 'Nutritional interventions'</a> and  <a class="medical medical_review" href="/d/html/1440.html" rel="external">"Malnutrition in advanced lung disease", section on 'Medications'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>CKD (see  <a class="medical medical_review" href="/d/html/1856.html" rel="external">"Pathogenesis and treatment of malnutrition in patients on maintenance hemodialysis", section on 'Nutritional supplements'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>End-stage liver disease (see  <a class="medical medical_review" href="/d/html/86296.html" rel="external">"Palliative care for patients with end-stage liver disease", section on 'Other symptoms'</a>)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 1997; 315:1219.</a></li><li><a class="nounderline abstract_t">Kotler DP. Cachexia. Ann Intern Med 2000; 133:622.</a></li><li><a class="nounderline abstract_t">McGeer AJ, Detsky AS, O'Rourke K. Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis. Nutrition 1990; 6:233.</a></li><li><a class="nounderline abstract_t">Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147:755.</a></li><li><a class="nounderline abstract_t">Kim TN, Yang SJ, Yoo HJ, et al. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study. Int J Obes (Lond) 2009; 33:885.</a></li><li><a class="nounderline abstract_t">Rolland Y, Lauwers-Cances V, Cristini C, et al. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l'OSteoporose) Study. Am J Clin Nutr 2009; 89:1895.</a></li><li><a class="nounderline abstract_t">Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9:629.</a></li><li><a class="nounderline abstract_t">Olden AM, Holloway R, Ladwig S, et al. Palliative care needs and symptom patterns of hospitalized elders referred for consultation. J Pain Symptom Manage 2011; 42:410.</a></li><li><a class="nounderline abstract_t">Laugsand EA, Kaasa S, de Conno F, et al. Intensity and treatment of symptoms in 3,030 palliative care patients: a cross-sectional survey of the EAPC Research Network. J Opioid Manag 2009; 5:11.</a></li><li><a class="nounderline abstract_t">Bosaeus I, Daneryd P, Svanberg E, Lundholm K. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer 2001; 93:380.</a></li><li><a class="nounderline abstract_t">Hutton JL, Martin L, Field CJ, et al. Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. Am J Clin Nutr 2006; 84:1163.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Block G, McAllister CJ, et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80:299.</a></li><li><a class="nounderline abstract_t">Hughes CM, Woodside JV, McGartland C, et al. Nutritional intake and oxidative stress in chronic heart failure. Nutr Metab Cardiovasc Dis 2012; 22:376.</a></li><li><a class="nounderline abstract_t">Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer 2013; 21:1569.</a></li><li><a class="nounderline abstract_t">von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010; 1:1.</a></li><li><a class="nounderline abstract_t">Ebner N, Springer J, Kalantar-Zadeh K, et al. Mechanism and novel therapeutic approaches to wasting in chronic disease. Maturitas 2013; 75:199.</a></li><li><a class="nounderline abstract_t">von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009; 121:227.</a></li><li><a class="nounderline abstract_t">Mak RH, Ikizler AT, Kovesdy CP, et al. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle 2011; 2:9.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42:864.</a></li><li><a class="nounderline abstract_t">Wanke CA, Silva M, Knox TA, et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 31:803.</a></li><li><a class="nounderline abstract_t">Campa A, Yang Z, Lai S, et al. HIV-related wasting in HIV-infected drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 41:1179.</a></li><li><a class="nounderline abstract_t">Siddiqui J, Samuel SK, Hayward B, et al. HIV-associated wasting prevalence in the era of modern antiretroviral therapy. AIDS 2022; 36:127.</a></li><li><a class="nounderline abstract_t">Cone RD. The Central Melanocortin System and Energy Homeostasis. Trends Endocrinol Metab 1999; 10:211.</a></li><li><a class="nounderline abstract_t">Elmquist JK. Anatomic basis of leptin action in the hypothalamus. Front Horm Res 2000; 26:21.</a></li><li><a class="nounderline abstract_t">Sleeman MW, Anderson KD, Lambert PD, et al. The ciliary neurotrophic factor and its receptor, CNTFR alpha. Pharm Acta Helv 2000; 74:265.</a></li><li><a class="nounderline abstract_t">Williams G, Harrold JA, Cutler DJ. The hypothalamus and the regulation of energy homeostasis: lifting the lid on a black box. Proc Nutr Soc 2000; 59:385.</a></li><li><a class="nounderline abstract_t">Woods SC, Schwartz MW, Baskin DG, Seeley RJ. Food intake and the regulation of body weight. Annu Rev Psychol 2000; 51:255.</a></li><li><a class="nounderline abstract_t">Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409:194.</a></li><li><a class="nounderline abstract_t">Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407:908.</a></li><li><a class="nounderline abstract_t">Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62:413.</a></li><li><a class="nounderline abstract_t">Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395:763.</a></li><li><a class="nounderline abstract_t">Soeters PB, Grimble RF. Dangers, and benefits of the cytokine mediated response to injury and infection. Clin Nutr 2009; 28:583.</a></li><li><a class="nounderline abstract_t">Argilés JM, Alvarez B, López-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev 1997; 17:477.</a></li><li><a class="nounderline abstract_t">Sarkisian CA, Lachs MS. "Failure to thrive" in older adults. Ann Intern Med 1996; 124:1072.</a></li><li><a class="nounderline abstract_t">Hamerman D. Toward an understanding of frailty. Ann Intern Med 1999; 130:945.</a></li><li><a class="nounderline abstract_t">Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database Syst Rev 2014; :CD011056.</a></li><li><a class="nounderline abstract_t">Damrauer JS, Stadler ME, Acharyya S, et al. Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia. Eur J Transl Myol 2018; 28:7590.</a></li><li><a class="nounderline abstract_t">Carrero JJ, Qureshi AR, Axelsson J, et al. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 2007; 85:695.</a></li><li><a class="nounderline abstract_t">Heckel M, Stiel S, Ostgathe C. Smell and taste in palliative care: a systematic analysis of literature. Eur Arch Otorhinolaryngol 2015; 272:279.</a></li><li><a class="nounderline abstract_t">Rubinstein AL, Carpenter DM, Minkoff JR. Hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids. Clin J Pain 2013; 29:840.</a></li><li><a class="nounderline abstract_t">Rubinstein A, Carpenter DM. Elucidating risk factors for androgen deficiency associated with daily opioid use. Am J Med 2014; 127:1195.</a></li><li><a class="nounderline abstract_t">Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236.</a></li><li><a class="nounderline abstract_t">Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest 1999; 115:836.</a></li><li><a class="nounderline abstract_t">Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001; 104:2034.</a></li><li><a class="nounderline abstract_t">Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997; 30:527.</a></li><li><a class="nounderline abstract_t">Araújo JP, Lourenço P, Rocha-Gonçalves F, et al. Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail 2009; 11:567.</a></li><li><a class="nounderline abstract_t">Debigaré R, Côté CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am J Respir Crit Care Med 2001; 164:1712.</a></li><li><a class="nounderline abstract_t">Benedik B, Farkas J, Kosnik M, et al. Mini nutritional assessment, body composition, and hospitalisations in patients with chronic obstructive pulmonary disease. Respir Med 2011; 105 Suppl 1:S38.</a></li><li><a class="nounderline abstract_t">Mitch WE. Insights into the abnormalities of chronic renal disease attributed to malnutrition. J Am Soc Nephrol 2002; 13 Suppl 1:S22.</a></li><li><a class="nounderline abstract_t">Mitch WE. Proteolytic mechanisms, not malnutrition, cause loss of muscle mass in kidney failure. J Ren Nutr 2006; 16:208.</a></li><li><a class="nounderline abstract_t">Del Fabbro E, Hui D, Dalal S, et al. Clinical outcomes and contributors to weight loss in a cancer cachexia clinic. J Palliat Med 2011; 14:1004.</a></li><li><a class="nounderline abstract_t">Dev R, Hui D, Del Fabbro E, et al. Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer. Cancer 2014; 120:1586.</a></li><li><a class="nounderline abstract_t">Kwang AY, Kandiah M. Objective and subjective nutritional assessment of patients with cancer in palliative care. Am J Hosp Palliat Care 2010; 27:117.</a></li><li><a class="nounderline abstract_t">Rhondali W, Chisholm GB, Daneshmand M, et al. Association between body image dissatisfaction and weight loss among patients with advanced cancer and their caregivers: a preliminary report. J Pain Symptom Manage 2013; 45:1039.</a></li><li><a class="nounderline abstract_t">Oberholzer R, Hopkinson JB, Baumann K, et al. Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. J Pain Symptom Manage 2013; 46:77.</a></li><li><a class="nounderline abstract_t">Del Río MI, Shand B, Bonati P, et al. Hydration and nutrition at the end of life: a systematic review of emotional impact, perceptions, and decision-making among patients, family, and health care staff. Psychooncology 2012; 21:913.</a></li><li><a class="nounderline abstract_t">Raijmakers NJ, Clark JB, van Zuylen L, et al. Bereaved relatives' perspectives of the patient's oral intake towards the end of life: a qualitative study. Palliat Med 2013; 27:665.</a></li><li><a class="nounderline abstract_t">Yamagishi A, Morita T, Miyashita M, et al. The care strategy for families of terminally ill cancer patients who become unable to take nourishment orally: recommendations from a nationwide survey of bereaved family members' experiences. J Pain Symptom Manage 2010; 40:671.</a></li><li><a class="nounderline abstract_t">Dev R. Measuring cachexia-diagnostic criteria. Ann Palliat Med 2019; 8:24.</a></li><li><a class="nounderline abstract_t">Blauwhoff-Buskermolen S, Ruijgrok C, Ostelo RW, et al. The assessment of anorexia in patients with cancer: cut-off values for the FAACT-A/CS and the VAS for appetite. Support Care Cancer 2016; 24:661.</a></li><li><a class="nounderline abstract_t">Del Fabbro E, Jatoi A, Davis M, et al. Health professionals' attitudes toward the detection and management of cancer-related anorexia-cachexia syndrome, and a proposal for standardized assessment. J Community Support Oncol 2015; 13:181.</a></li><li><a class="nounderline abstract_t">Thoresen L, Fjeldstad I, Krogstad K, et al. Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool. Palliat Med 2002; 16:33.</a></li><li><a class="nounderline abstract_t">Bauer J, Capra S, Ferguson M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr 2002; 56:779.</a></li><li><a class="nounderline abstract_t">Kondrup J, Rasmussen HH, Hamberg O, et al. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr 2003; 22:321.</a></li><li><a class="nounderline abstract_t">Omran ML, Morley JE. Assessment of protein energy malnutrition in older persons, Part II: Laboratory evaluation. Nutrition 2000; 16:131.</a></li><li><a class="nounderline abstract_t">Cansado P, Ravasco P, Camilo M. A longitudinal study of hospital undernutrition in the elderly: comparison of four validated methods. J Nutr Health Aging 2009; 13:159.</a></li><li><a class="nounderline abstract_t">Boléo-Tomé C, Chaves M, Monteiro-Grillo I, et al. Teaching nutrition integration: MUST screening in cancer. Oncologist 2011; 16:239.</a></li><li><a class="nounderline abstract_t">Blum D, Strasser F. Cachexia assessment tools. Curr Opin Support Palliat Care 2011; 5:350.</a></li><li><a class="nounderline abstract_t">Bingham J. The dietary assessment of individuals; methods accuracy, new techniques and recommendations. Nutrition Abstracts Review 1987; 57:705.</a></li><li><a class="nounderline abstract_t">von Gruenigen VE, Courneya KS, Gibbons HE, et al. Feasibility and effectiveness of a lifestyle intervention program in obese endometrial cancer patients: a randomized trial. Gynecol Oncol 2008; 109:19.</a></li><li><a class="nounderline abstract_t">Bruera E, Chadwick S, Cowan L, et al. Caloric intake assessment in advanced cancer patients: comparison of three methods. Cancer Treat Rep 1986; 70:981.</a></li><li><a class="nounderline abstract_t">Romero-Corral A, Somers VK, Sierra-Johnson J, et al. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (Lond) 2008; 32:959.</a></li><li><a class="nounderline abstract_t">Kyle UG, Unger P, Dupertuis YM, et al. Body composition in 995 acutely ill or chronically ill patients at hospital admission: a controlled population study. J Am Diet Assoc 2002; 102:944.</a></li><li><a class="nounderline abstract_t">Martin L, Senesse P, Gioulbasanis I, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 2015; 33:90.</a></li><li><a class="nounderline abstract_t">Ellegård LH, Ahlén M, Körner U, et al. Bioelectric impedance spectroscopy underestimates fat-free mass compared to dual energy X-ray absorptiometry in incurable cancer patients. Eur J Clin Nutr 2009; 63:794.</a></li><li><a class="nounderline abstract_t">Roeland EJ, Bohlke K, Baracos VE, et al. Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol 2020; 38:2438.</a></li><li><a class="nounderline abstract_t">Good P, Cavenagh J, Mather M, Ravenscroft P. Medically assisted nutrition for palliative care in adult patients. Cochrane Database Syst Rev 2008; :CD006274.</a></li><li><a class="nounderline abstract_t">Hoda D, Jatoi A, Burnes J, et al. Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution's 20-year experience. Cancer 2005; 103:863.</a></li><li><a class="nounderline abstract_t">Brard L, Weitzen S, Strubel-Lagan SL, et al. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol Oncol 2006; 103:176.</a></li><li class="breakAll">Megestrol acetate. United States prescribing information. Revised December 2018. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021778s024lbl.pdf (Accessed on August 21, 2023).</li><li><a class="nounderline abstract_t">Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993; 11:762.</a></li><li><a class="nounderline abstract_t">Brown TJ, Gandhi S, Smith TJ, Gupta A. Lessons from spending on megestrol for cancer cachexia. Support Care Cancer 2021; 29:5553.</a></li><li><a class="nounderline abstract_t">Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994; 121:400.</a></li><li><a class="nounderline abstract_t">Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994; 121:393.</a></li><li><a class="nounderline abstract_t">Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2013; :CD004310.</a></li><li><a class="nounderline abstract_t">Piepoli MF, Davos C, Francis DP, et al. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004; 328:189.</a></li><li><a class="nounderline abstract_t">van de Bool C, Rutten EPA, van Helvoort A, et al. A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. J Cachexia Sarcopenia Muscle 2017; 8:748.</a></li><li><a class="nounderline abstract_t">Morgan CJ, Freeman TP, Powell J, Curran HV. AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Transl Psychiatry 2016; 6:e738.</a></li><li><a class="nounderline abstract_t">Pasha AK, Clements CY, Reynolds CA, et al. Cardiovascular Effects of Medical Marijuana: A Systematic Review. Am J Med 2021; 134:182.</a></li><li><a class="nounderline abstract_t">Maida V, Daeninck PJ. A user's guide to cannabinoid therapies in oncology. Curr Oncol 2016; 23:398.</a></li><li><a class="nounderline abstract_t">Abrams DI. Integrating cannabis into clinical cancer care. Curr Oncol 2016; 23:S8.</a></li><li><a class="nounderline abstract_t">Alderman B, Hui D, Mukhopadhyay S, et al. Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer. Support Care Cancer 2022; 31:39.</a></li><li><a class="nounderline abstract_t">Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 1988; 148:1586.</a></li><li><a class="nounderline abstract_t">Wong CS, Gipson DS, Gillen DL, et al. Anthropometric measures and risk of death in children with end-stage renal disease. Am J Kidney Dis 2000; 36:811.</a></li><li><a class="nounderline abstract_t">Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349:1050.</a></li><li><a class="nounderline abstract_t">Wheeler DA, Gibert CL, Launer CA, et al. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:80.</a></li><li><a class="nounderline abstract_t">Guenter P, Muurahainen N, Simons G, et al. Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr 1993; 6:1130.</a></li><li><a class="nounderline abstract_t">Morishita S, Kaida K, Tanaka T, et al. Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation. Support Care Cancer 2012; 20:3161.</a></li><li><a class="nounderline abstract_t">Capuano G, Gentile PC, Bianciardi F, et al. Prevalence and influence of malnutrition on quality of life and performance status in patients with locally advanced head and neck cancer before treatment. Support Care Cancer 2010; 18:433.</a></li></ol></div><div id="topicVersionRevision">Topic 83234 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9393230" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ABC of palliative care. Anorexia, cachexia, and nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11033592" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2152097" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554417" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology of sarcopenia among the elderly in New Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19564878" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19369381" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l'OSteoporose) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539529" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444188" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Palliative care needs and symptom patterns of hospitalized elders referred for consultation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344044" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Intensity and treatment of symptoms in 3,030 palliative care patients: a cross-sectional survey of the EAPC Research Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11433403" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17093170" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277149" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21186107" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nutritional intake and oxidative stress in chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23314651" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21475699" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cachexia as a major underestimated and unmet medical need: facts and numbers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23664695" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mechanism and novel therapeutic approaches to wasting in chronic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19061914" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cardiac cachexia: a systematic overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21475675" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Wasting in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14582032" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017833" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16163638" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : HIV-related wasting in HIV-infected drug users in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34628440" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : HIV-associated wasting prevalence in the era of modern antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10407394" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Central Melanocortin System and Energy Homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10767939" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Anatomic basis of leptin action in the hypothalamus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10812968" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The ciliary neurotrophic factor and its receptor, CNTFR alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10997654" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The hypothalamus and the regulation of energy homeostasis: lifting the lid on a black box.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10751972" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Food intake and the regulation of body weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11196643" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A role for ghrelin in the central regulation of feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11057670" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ghrelin induces adiposity in rodents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10845097" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Leptin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9796811" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Leptin and the regulation of body weight in mammals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19556039" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dangers, and benefits of the cytokine mediated response to injury and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9276862" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The metabolic basis of cancer cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633822" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : "Failure to thrive" in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10375351" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Toward an understanding of frailty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24874470" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29991992" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17344489" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705604" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Smell and taste in palliative care: a systematic analysis of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24384986" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25063648" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Elucidating risk factors for androgen deficiency associated with daily opioid use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2195340" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084500" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11673342" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9247528" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19359328" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adiponectin is increased in cardiac cachexia irrespective of body mass index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11719314" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22015084" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mini nutritional assessment, body composition, and hospitalisations in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11792758" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Insights into the abnormalities of chronic renal disease attributed to malnutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16825021" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Proteolytic mechanisms, not malnutrition, cause loss of muscle mass in kidney failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21793729" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical outcomes and contributors to weight loss in a cancer cachexia clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24577665" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19959839" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Objective and subjective nutritional assessment of patients with cancer in palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23102755" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Association between body image dissatisfaction and weight loss among patients with advanced cancer and their caregivers: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23159682" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22162174" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hydration and nutrition at the end of life: a systematic review of emotional impact, perceptions, and decision-making among patients, family, and health care staff.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23442880" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bereaved relatives' perspectives of the patient's oral intake towards the end of life: a qualitative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20800425" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The care strategy for families of terminally ill cancer patients who become unable to take nourishment orally: recommendations from a nationwide survey of bereaved family members' experiences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30525765" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Measuring cachexia-diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26160463" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The assessment of anorexia in patients with cancer: cut-off values for the FAACT-A/CS and the VAS for appetite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26029935" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Health professionals' attitudes toward the detection and management of cancer-related anorexia-cachexia syndrome, and a proposal for standardized assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11963449" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12122555" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12765673" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10696638" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Assessment of protein energy malnutrition in older persons, Part II: Laboratory evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19214346" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A longitudinal study of hospital undernutrition in the elderly: comparison of four validated methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21273515" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Teaching nutrition integration: MUST screening in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21986911" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cachexia assessment tools.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The dietary assessment of individuals; methods accuracy, new techniques and recommendations</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18243282" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Feasibility and effectiveness of a lifestyle intervention program in obese endometrial cancer patients: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3731154" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Caloric intake assessment in advanced cancer patients: comparison of three methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18283284" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Accuracy of body mass index in diagnosing obesity in the adult general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12146557" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Body composition in 995 acutely ill or chronically ill patients at hospital admission: a controlled population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422490" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Diagnostic criteria for the classification of cancer-associated weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18478025" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Bioelectric impedance spectroscopy underestimates fat-free mass compared to dual energy X-ray absorptiometry in incurable cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32432946" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Management of Cancer Cachexia: ASCO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843710" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Medically assisted nutrition for palliative care in adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15641035" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution's 20-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16564074" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16564074" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8478668" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33893560" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Lessons from spending on megestrol for cancer cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8053613" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Megestrol acetate in patients with AIDS and cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7794302" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Megestrol acetate in patients with AIDS-related cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543530" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Megestrol acetate for treatment of anorexia-cachexia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14729656" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28608438" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26882038" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33186596" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cardiovascular Effects of Medical Marijuana: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28050136" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A user's guide to cannabinoid therapies in oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27022315" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Integrating cannabis into clinical cancer care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36525085" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3382303" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Clinical symptoms and length of survival in patients with terminal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007685" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Anthropometric measures and risk of death in children with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9107242" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Wasting as independent risk factor for mortality in chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593462" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8105073" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Relationships among nutritional status, disease progression, and survival in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22526152" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19562384" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Prevalence and influence of malnutrition on quality of life and performance status in patients with locally advanced head and neck cancer before treatment.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
